News Headlines Article

Diabetes drug developer NGM Biopharma, led by Genentech vets Levinson and Goeddel, raises $13.5 million
San Francisco Business Times

Drug developer NGM Biopharmaceuticals Inc., which counts big-time Genentech Inc. names like Art Levinson and Dave Goeddel among its leadership, raised nearly $13.5 million toward a $50 million goal. The South San Francisco company, which in January inked a diabetes drug deal with Janssen Pharmaceuticals Inc., said in a Securities and Exchange Commission filing Thursday that 14 investors have stepped up since the equity offering began April 9.

Commands